$RGBP Currently the Company is developing products
Post# of 26730
(Total Views: 269)
Posted On: 03/02/2017 9:06:01 AM
$RGBP Currently the Company is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
(0)
(0)Scroll down for more posts ▼